| Description | This product is a human monoclonal antibody that reacts with IL17RA. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human |
| Isotype | IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | WB; DB; Neut; ELISA; IF; IP; FuncS; FC; ICC |
| Application Notes | The antibody is recommended for detection of IL17RA by Neut, ELISA, IF, IP, FuncS, FC, ICC assays. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
Figure 1 Anti-Human IL17RA Monoclonal Antibody (V3S-0622-YC1899) in ELISA
ELISA analysis of V3S-0622-YC1899 was performed by coating with Human IL17RA Protein (His Tag). Then blocked with BSA and incubated with V3S-0622-YC1899. The HRP-conjugated goat anti-human IgG as a secondary antibody (1:6000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 1 Anti-Human IL17RA Monoclonal Antibody (V3S-0622-YC1899) in ELISA
Figure 2 Anti-Human IL17RA Monoclonal Antibody (V3S-0622-YC1899) in WB
Western blot analysis of V3S-0622-YC1899 was performed by loading Human IL17RA Protein (His Tag) in reduced condition Lane 1 (Non-reducing antigen, 0.5 μg) and Lane 2 (Reducing antigen, 0.5 μg) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0622-YC1899 (2 μg/mL) and HRP-conjugated goat anti-human IgG as a secondary antibody (1:6000). Chemiluminescent detection was performed.
Figure 2 Anti-Human IL17RA Monoclonal Antibody (V3S-0622-YC1899) in WB
Figure 3 Anti-Human IL17RA Monoclonal Antibody (V3S-0622-YC1899) in SDS-PAGE
SDS-PAGE analysis of V3S-0622-YC1899 in non-reduced (lane 1) and β-mercaptoethanol-reduced (lane 2) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively. And non-reduced protein migrates as 130-180 kDa.
Figure 3 Anti-Human IL17RA Monoclonal Antibody (V3S-0622-YC1899) in SDS-PAGE
Figure 4 Anti-Human IL17RA Monoclonal Antibody (V3S-0622-YC1899) in SEC-HPLC
The purity of V3S-0622-YC1899 was greater than 95% as determined by SEC-HPLC.
Column: 3 µm, 7.8 x 300 nm
Mobile phase: 150 mM Sodium Phosphate Buffer, pH 7.0
Detection: UV 280 nm
Injection: 10 µl
Figure 4 Anti-Human IL17RA Monoclonal Antibody (V3S-0622-YC1899) in SEC-HPLC
Figure 5 Anti-Human IL17RA Monoclonal Antibody (V3S-0622-YC1899) in ELISA
ELISA analysis of V3S-0622-YC1899 was performed by coating with Human IL17RA Protein (His Tag). Then blocked with BSA and incubated with V3S-0622-YC1899. The HRP-conjugated goat anti-human IgG as a secondary antibody (1: 5000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 5 Anti-Human IL17RA Monoclonal Antibody (V3S-0622-YC1899) in ELISA
Figure 6 Anti-Human IL17RA Monoclonal Antibody (V3S-0622-YC1899) in WB
Western blot analysis of V3S-0622-YC1899 was performed by loading Human IL17RA Protein (His Tag) in reduced condition Lane 1, Lane 2 and Lane 3 (0.1 μg, 0.3 μg and 0.6 μg respectively) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0622-YC1899 (2 μg/mL) and HRP-conjugated goat anti-human IgG as a secondary antibody (1: 6000). Chemiluminescent detection was performed.
Figure 6 Anti-Human IL17RA Monoclonal Antibody (V3S-0622-YC1899) in WB
Figure 7 Anti-Human IL17RA Monoclonal Antibody (V3S-0622-YC1899) in DB
Dot Blot analysis of V3S-0622-YC1899 was performed by coating with Human IL17RA Protein (His Tag).
V3S-0622-YC1899 incubation concentration: 2 μg/mL.
HRP goat anti-human IgG as a secondary antibody (1: 6000)
NC: Negative control PC: Positive control
Figure 7 Anti-Human IL17RA Monoclonal Antibody (V3S-0622-YC1899) in DB
